Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is a biotechnology business that develops, manufactures, and distributes medicines for people with rare metabolic illnesses. The Company is working on a pipeline of medications for uncommon metabolic diseases, including a gene therapy portfolio of rare illnesses. It has a pharmaceutical portfolio that includes oral precision medicine for Fabry disease.

Key Highlights:

• Despite stellar topline performance, the company reported net losses of USD 250.5 million in FY21.
• The Company’s business could suffer considerably if it is unable to commercialise Galafold® successfully.
• Brexit's influence on its overseas activities could significantly impact the Company.
• The Company had recorded significant negative returns on equity of -24.4% in Q3 FY22 compared to the industry median of -7.3%, resulting in liquidity risk.
• The mounting concern over the Russian invasion of Ukraine can continue to weigh on the equity market.
• From a technical standpoint, the Stock is now trading below its critical support level of the 50 and 200-day SMAs along with death crossover, indicating a bearish trend.

Stock Recommendation

Based on the recurring losses, single product concentration, international activities, associated risks, and unfavourable technical indicators, we recommend an "Avoid" rating on the stock at the closing price of USD 8.25, down 2.71% as of February 25, 2022.

1-Year Technical Price Chart (as of February 25, 2022). Source: REFINITIV, Analysis by Kalkine Group

 *The reference data in this report has been partly sourced from REFINITIV

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.